文献速递淋巴瘤

慢性淋巴细胞白血病基因组与转录组景观:275例整合分析

The genomic and transcriptomic landscape of chronic lymphocytic leukaemia: Insights from an integrated analysis of 275 patients.
PubMed 文献 · Br J Haematol · 2026-10-23

该研究对275例慢性淋巴细胞白血病(CLL)患者进行整合分析,采用二代测序评估突变、基因重排和RNA表达,并结合细胞遗传学/FISH、IGHV状态和临床结局。结果显示TP53、NOTCH1、ATM、BIRC3和SF3B1为最常见突变基因,KRAS突变与较差总生存独立相关,XPO1突变和年龄≥65岁为至首次治疗时间的不良因素。无突变患者疾病特征更有利。

要点

  • KRAS突变与CLL患者较差总生存独立相关。
  • XPO1突变和年龄≥65岁是至首次治疗时间的不良因素。
  • 无突变患者具有更有利特征:IGHV突变、较少细胞遗传学异常、较长TTFT。

核心结论

  • 整合基因组和转录组分析可识别CLL中具有临床相关性的分子亚群,可能改进风险分层。

研究设计与样本

  • 研究分析了275例CLL患者,使用综合二代测序检测突变、基因重排和RNA表达,并整合细胞遗传学/FISH数据、IGHV状态和临床结局。

主要发现

  • 最常见突变基因为TP53、NOTCH1、ATM、BIRC3和SF3B1。
  • RNA分析显示B细胞相关基因反复上调,包括PAX5、CREB3L2、FOXP1、SH3BP5、CCDC50和PTPN1。
  • 鉴定出新的基因重排,包括CBFB::DNTTIP1、IGH::PDCD1LG2和PPP2R5C::TERT。
  • KRAS突变与较差总生存独立相关;XPO1突变和年龄≥65岁是至首次治疗时间的不良因素。
  • 无突变患者具有更有利疾病特征:IGHV突变、较少细胞遗传学异常、较高13q缺失率、较低17p缺失率和较长TTFT。

关键数值与推荐

  • KRAS突变与较差OS独立相关;XPO1突变和年龄≥65岁为TTFT不良因素。
  • 无突变患者中IGHV突变率更高、细胞遗传学异常更少、13q缺失率更高、17p缺失率更低、TTFT更长。

临床怎么用

  • 对CLL患者进行整合基因组和转录组分析可能有助于识别高风险亚群并指导风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukaemia (CLL) exhibits marked clinical and molecular heterogeneity. While previous studies have primarily focused on gene mutations, the broader landscape of genomic alterations and their clinical significance remains incompletely characterized. We analysed 275 patients with CLL using a comprehensive next-generation sequencing assay that assessed mutations, gene rearrangements and ribonucleic acid (RNA) expression, integrated with cytogenetic/fluorescence in situ hybridization (FISH) data, immunoglobulin heavy chain variable region (IGHV) status and clinical outcomes. The most frequently mutated genes were TP53, NOTCH1, ATM, BIRC3 and SF3B1. RNA analysis revealed recurrent upregulation of B-cell-associated genes, including PAX5, CREB3L2, FOXP1, SH3BP5, CCDC50 and PTPN1. Novel gene rearrangements were identified, including CBFB::DNTTIP1, IGH::PDCD1LG2 and PPP2R5C::TERT. KRAS mutation was independently associated with inferior overall survival (OS), whereas XPO1 mutation and age ≥ 65 years were adverse factors for time to first treatment (TTFT). Patients without detectable mutations exhibited more favourable disease features, including mutated IGHV, fewer cytogenetic abnormalities, higher rates of increased 13q deletion, lower rates of 17p deletion and longer TTFT. Although elevated RNA expression was not directly associated with OS or TTFT, distinct mutation-associated expression patterns were observed. These findings demonstrate that integrated genomic and transcriptomic profiling can identify clinically relevant molecular subsets in CLL, potentially refining risk stratification and informing future studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Afkhami M, Ma H, Telatar M, et al. The genomic and transcriptomic landscape of chronic lymphocytic leukaemia: Insights from an integrated analysis of 275 patients. Br J Haematol. 2026. PMID: 42922293. doi:10.1111/bjh.70910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。